receiving a kidney transplant. Belatacept is approved for use in combination with other immunosuppressants , specifically basiliximab, mycophenolate mofetil and corticosteroids. Belatacept is a potent antagonist that inhibits T-lymphocyte activation by binding to the B7-ligands , namely CD80 (Uniprot: P33681 ; Pfam: PF08205 , PF07686 ) and CD86 (Uniprot: P42081 ;